OncoMatch/Clinical Trials/NCT06492070
Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
Is NCT06492070 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Cilostazol and Cryocompression Therapy for cervical carcinoma.
Treatment: Cilostazol · Cryocompression Therapy · Paclitaxel — The phase II trial evaluates the effectiveness of cryocompression therapy alone or in combination with cilostazol in preventing paclitaxel-induced peripheral neuropathy (numbness, pain or tingling in the feet and hands) for patients with gynecologic cancers. Peripheral neuropathy is a common side effect of many chemotherapeutic agents, including paclitaxel. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Cryocompression is a therapy that combines compression garments or dressings with cooling of the treated area. Cilostazol is in a class of medications called platelet-aggregation inhibitors (antiplatelet medications). It works by improving blood flow to the legs. Giving cilostazol together with cryocompression may be safe and tolerable in treating patients with gynecological cancers.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Ovarian Cancer
Tumor Agnostic
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: paclitaxel and carboplatin or cisplatin (paclitaxel, carboplatin, cisplatin) — planned (Arms A/B) or completed within last 3 months (Arm C)
planned chemotherapy regimen of 6-9 cycles of paclitaxel and carboplatin or cisplatin... (Arms A/B); completion of 6-9 cycles...within the last 3 months (Arm C)
Cannot have received: paclitaxel (paclitaxel)
Previous treatment with paclitaxel
Lab requirements
Blood counts
white blood count >= 4,000/mm^3 and platelet count >= 100,000/mm^3
Kidney function
serum creatinine < 1.5mg/dL
Liver function
No moderate to severe hepatic impairment (Class B & C by Child-Pugh score); serum total bilirubin < 1.5mg/dL
Cardiac function
No high risk uncontrolled arrhythmias or ischemic heart disease
Inadequate bone marrow function with white blood count < 4,000/mm^3 and platelet count < 100,000/mm^3; Inadequate liver function with serum total bilirubin >= 1.5mg/dL; Inadequate renal function with serum creatinine >= 1.5mg/dL; Hepatic impairment, moderate to severe (Class B & C by Child-Pugh score); High risk uncontrolled arrhythmias; Ischemic heart disease
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Emory University Hospital Midtown · Atlanta, Georgia
- Emory University Hospital/Winship Cancer Institute · Atlanta, Georgia
- Emory Saint Joseph's Hospital · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify